articles over the past 25 yr have been identified. We have asked the authors from 1 of these most cited papers to editorialize on changes occurring since the publication of their highly impactful paper. We believe that this frequently cited paper represents benchmarks of the progress in toxicologic pathology, and the authors are therefore thought leaders in the relevant technology. The following invited editorial by Drs. Haseman, Boorman, and Huff addresses the use of historical control data as well as other trends in cancer hazard identification studies.
key issues has been the use of historical control data in the evaluation and interpretation of experimental results. Our paper appeared at the right time, in the right journal, on the right topic, and hence received considerable scientific scrutiny and citations. The primary value of our paper is 2-fold: (a) it discusses the principles associated with the proper use of historical control data, describing both the value and limitations of such information in the interpretation of experimental results; and (b) it presents detailed control tumor incidence data for Fischer-344 (F-344) rats and B6C3F, mice, the animal models used most frequently by the National Toxicology Program (NTP) and by other investigators.
Since publication of this paper, background tumor rates have changed (19, 25) , but the basic principles regarding the use of historical control data remain the same. Historical control tumor data are useful in the interpretation of rodent carcinogenicity studies, especially for uncommonly occurring tumors and for marginal carcinogenic effects. However, the continuing challenge is to establish a database that is truly comparable to the study under evaluation with respect to those factors known to influence tumor occurrence.
One of the most important of these factors is consistency of gross necropsy and histopathology procedures, including the interpretation and classification of lesions. National Toxicology Program experimental protocols are structured to ensure that standard procedures are followed and that the data receive a thorough quality assurance and peer review before the nonneoplastic and neoplastic diagnoses are finalized (6, 16, 54) .
Another critical variable that influences the use of historical control data is body weight. In the decade since publication of our 1984 Toxicologic Pathology paper (22) , control F-344 rats in NTP long-term rodent carcinogenicity studies have shown steady time-related increases in body weight and certain tumor incidences, with corresponding decreases in survival (18, 27, 46, 52) . More recently, B6C3F, mice have shown a similar trend (17, 20) . A major reason for this gradual increase in body weight may be the intentional or inadvertent selection of breeding stock for faster growth and earlier reproduction to satisfy user preference for larger rodents at low cost (45) . Thus, comparability of body weight is an important factor that must be considered in the use of historical control data.
Other factors that may produce differences in control tumor rates from study to study include caging protocols, diet, environmental factors, genetic drift, study duration, and survival differences (20, 24) . In practice, the number of truly comparable studies over time may be relatively small, so the availability of relevant historical control data for contemporary studies may be limited (18) . Thus, primary emphasis should continue to be given to concurrent rather than to historical control data when interpreting experimental results.
Use of historical control data is only one of many issues that continue to be discussed and debated regarding the value of long-term rodent carcinogenicity studies (29, 33) . Proper dose selection continues to be an important issue (5, 8, 15, 26, 33) . It has been suggested that a reduced protocol (e.g., male rats and female mice or male and female rats) may be sufficient for detecting the majority of important carcinogens (3, 14, 21, 39, 40) . The development of biological models of carcinogenesis for quantitative cancer risk assessment continues to be an area of active research (10, 41) .
Recently, there has been increased interest in dietary restriction or dietary control to reduce body weight, improve survival, and lower background tumor rates (1, 4) . Dietary restriction protocols fall into 2 broad categories. The first approach is to impose the same moderate degree of food restriction on dosed and control animals, which may or may not result in dosed and control groups of equivalent size (36) (37) (38) . The second approach is to food restrict animals so that they have the same &dquo;idealized&dquo; body weight (53) , which may or may not require equal degrees of food restriction in dosed and control groups. While eliminating obesity and improving survival are worthy goals, data from the NTP Dietary Restriction study suggest that the use of moderate food restriction may reduce study sensitivity for detecting carcinogenic effects (1) .
A third option for controlling body weight is to change the formulation of the diet and/or to require smaller animals with slower growth rates from the breeder. While this approach may not have as immediate an effect on body weight and tumor incidences as dietary restriction, it has the advantage of treating the underlying cause of the problem rather than the symptoms (44, 45) .
During the past decade, there has been a greater emphasis on understanding the mechanisms of action that may be responsible for the carcinogenic effects observed. Consistent with this philosophy, the criteria for listing chemicals in the NTP's Report on Carcinogens (RC) (42) have been revised to include mechanistic considerations.
For example, the RC states that &dquo;there may be substances for which there is evidence of carcinogenicity in laboratory animals but there are compelling data indicating that the agent acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans&dquo; (42) . Such chemicals would not be listed as &dquo;reasonably anticipated to be human carcinogens&dquo; in the RC. Conversely, the RC allows for a chemical with &dquo;less than sufficient evidence of carcinogenicity in humans or laboratory animals&dquo; to nevertheless be categorized as &dquo;reasonably anticipated&dquo; to be a human carcinogen if &dquo;there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.&dquo;
The increasing emphasis on mechanism has led to an increased research focus on certain specific tumor end points in rodents that some investigators believe are produced by mechanisms that are of questionable relevance to humans (9, 13) . This is an important issue, since the questioned tumor sites constitute a significant portion of the carcinogenic effects found in rodent studies (35) , and determining definitive mechanisms of carcinogenic action may be difficult (31, 32) .
Other areas of current research include a search for alternative methods of testing that are as predictive of human cancer risk as is the standard 2-yr bioassay, but can be conducted in a shorter time frame, with less expense, and requiring fewer animals, personnel, and facilities (2, 48) . The 1993 NIH Revitalization Act directed the various NIH Institutes to develop and validate alternative methods for acute and chronic safety testing that will reduce animal use, replace animals with nonanimal methods or lower species, or refine animal use to decrease or eliminate pain or distress. One potentially important new alternative screening system is the use of transgenic mouse lines, which provides the opportunity to develop relatively short-term in vivo models to identify carcinogens and other toxic agents. Such models include transgenic mice carrying reporter genes that may serve as targets for mutagenic events or mice carrying specific oncogenes or inactivated tumor-suppressor genes that are important factors contributing to the multistage process of carcinogenesis (11) . Mouse lines with defined genetic alterations that result in overexpression or inactivation of a gene intrinsic to carcinogenesis, but that are insufficient alone for neoplastic conversion, are promising models for chemical carcinogen identification and evaluation. Such studies may provide advantages in shortening the time required for bioassays and improving the accuracy of carcinogen identification (49, 50) .
Another area of current research is the use of artificial intelligence systems to predict carcinogenicity outcomes. Some of these methods are based on chemical structure (12) , while others are based on the activity of the test compound in surrogate biological test systems such as mutagenicity and short-term toxicity studies (51) . For an overview of these various methods, see Richards (47) .
While these methods continue to evolve and may ultimately reduce the need for rodent bioassays, their predictive accuracy at present (when applied prospectively under carefully controlled conditions) is limited (7, 28) .
In summary, since publication of our 1984 Toxicologic Pathology paper (22) , there have been considerable advances in our understanding of value and limitations of rodent carcinogenicity studies. Mechanistic research continues, and alternative test systems are being developed that may ultimately result in reduced reliance on the standard long-term bioassay. At present however, in the absence of human data, laboratory animal carcinogenicity studies remain the most definitive means for assessing a chemical's carcinogenic potential to humans (30, 34, 43) .
